CareDx, Inc. (CDNA)
Healthcare • Diagnostics & Research
StockNasdaqGMUnited StatesUS14167L1035
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by CareDx, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | 0.36 | — | — | Upcoming |
| 29 Oct 2026 16:00 | 0.26 | 0.70 | +174.5% | Beat |
| 30 Jul 2026 16:00 | 0.23 | 0.37 | +59.5% | Beat |
| 28 Apr 2026 16:00 | 0.13 | 0.34 | +161.5% | Beat |
| 24 Feb 2026 16:00 | 0.23 | 0.12 | -47.1% | Miss |
| 04 Nov 2025 16:00 | 0.14 | 0.28 | +97.6% | Beat |
| 06 Aug 2025 16:00 | 0.12 | 0.10 | -18.0% | Miss |
| 30 Apr 2025 16:00 | 0.07 | 0.10 | +46.4% | Beat |
| 26 Feb 2025 16:00 | 0.15 | 0.18 | +22.0% | Beat |
| 04 Nov 2024 16:00 | 0.01 | 0.14 | +1,099.7% | Beat |
| 31 Jul 2024 16:00 | -0.14 | 0.25 | +273.6% | Beat |
| 08 May 2024 20:00 | -0.21 | -0.03 | +85.4% | Beat |
| 28 Feb 2024 16:00 | -0.27 | -0.17 | +36.1% | Beat |
| 08 Nov 2023 16:00 | -0.40 | -0.18 | +54.6% | Beat |
| 08 Aug 2023 16:00 | -0.31 | -0.18 | +41.9% | Beat |
| 10 May 2023 16:00 | -0.10 | -0.11 | -7.8% | Miss |
| 27 Feb 2023 16:00 | -0.09 | -0.07 | +18.6% | Beat |
| 03 Nov 2022 16:00 | -0.14 | -0.06 | +57.1% | Beat |
| 04 Aug 2022 17:00 | -0.11 | -0.13 | -16.1% | Miss |
| 05 May 2022 17:00 | -0.04 | -0.13 | -205.9% | Miss |
| 24 Feb 2022 16:00 | 0.03 | -0.03 | -192.3% | Miss |
| 28 Oct 2021 17:00 | 0.02 | 0.07 | +250.0% | Beat |
| 29 Jul 2021 16:00 | 0.06 | 0.11 | +100.0% | Beat |
| 05 May 2021 16:00 | 0.01 | 0.14 | +2,700.0% | Beat |
| 24 Feb 2021 16:00 | 0.02 | 0.08 | +255.6% | Beat |
| 29 Oct 2020 17:00 | -0.06 | 0.10 | +266.7% | Beat |
| 04 Aug 2020 17:00 | -0.04 | 0.04 | +200.0% | Beat |
| 30 Apr 2020 16:00 | 0.03 | — | -100.0% | — |
| 27 Feb 2020 16:00 | 0.02 | 0.04 | +166.7% | Beat |
| 31 Oct 2019 16:00 | 0.01 | 0.02 | +100.0% | Beat |
| 01 Aug 2019 16:00 | — | — | -100.0% | — |
| 08 May 2019 16:00 | -0.04 | 0.05 | +215.4% | Beat |
| 06 Mar 2019 16:00 | 0.01 | 0.01 | 0.0% | In line |
| 08 Nov 2018 16:00 | -0.03 | -0.01 | +70.0% | Beat |
| 09 Aug 2018 16:00 | -0.07 | -0.04 | +42.9% | Beat |
| 10 May 2018 16:00 | -0.13 | -0.14 | -7.7% | Miss |
| 22 Mar 2018 16:00 | -0.13 | -0.09 | +30.8% | Beat |
| 09 Nov 2017 16:00 | -0.17 | -0.15 | +11.8% | Beat |
| 10 Aug 2017 16:00 | -0.20 | -0.17 | +15.0% | Beat |
| 09 Jun 2017 07:00 | -0.25 | -0.32 | -25.5% | Miss |
| 21 Apr 2017 16:00 | -0.17 | -0.13 | +22.0% | Beat |
| 09 Nov 2016 16:00 | -0.19 | -0.15 | +21.1% | Beat |
| 10 Aug 2016 16:00 | -0.27 | -0.29 | -7.4% | Miss |
| 06 May 2016 08:00 | -0.31 | -0.37 | -20.1% | Miss |
| 24 Mar 2016 16:00 | -0.35 | -0.37 | -6.3% | Miss |
| 11 Nov 2015 16:00 | -0.25 | -0.29 | -15.1% | Miss |
| 10 Aug 2015 16:00 | -0.18 | -0.27 | -52.8% | Miss |
| 13 May 2015 23:00 | -0.18 | -0.19 | -5.6% | Miss |
| 17 Mar 2015 16:00 | -0.11 | — | +102.4% | — |
| 10 Nov 2014 16:00 | -0.13 | -0.01 | +92.1% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 379.8M | +13.8% | -21.4M | -5.6% | -0.40 | -143.0% | 35.4M |
| 2024 | 333.8M | +19.1% | 52.5M | 15.7% | 0.93 | +126.3% | 31.6M |
| 2023 | 280.3M | -12.9% | -190.3M | -67.9% | -3.54 | -145.8% | -27.6M |
| 2022 | 321.8M | — | -76.6M | -23.8% | -1.44 | — | -49.6M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 87.47 | 90.05 | 75.81 | 77.32 | -11.55% | 12,465,241 | |
| Oct 2026 | 64.96 | 90.87 | 61.19 | 87.41 | +34.48% | 32,034,700 | |
| Sep 2026 | 49.93 | 65.63 | 48.25 | 65.00 | +29.71% | 26,354,100 | |
| Aug 2026 | 47.22 | 53.67 | 44.54 | 50.11 | +14.64% | 25,213,900 | |
| Jul 2026 | 28.71 | 45.00 | 27.32 | 43.71 | +53.37% | 25,704,200 | |
| Jun 2026 | 22.73 | 29.58 | 21.58 | 28.50 | +24.89% | 20,358,200 | |
| May 2026 | 20.97 | 23.09 | 19.62 | 22.82 | +9.66% | 12,810,400 | |
| Apr 2026 | 17.76 | 23.24 | 15.56 | 20.81 | +19.87% | 17,010,200 | |
| Mar 2026 | 18.45 | 19.33 | 16.24 | 17.36 | -7.46% | 13,567,500 | |
| Feb 2026 | 20.37 | 21.40 | 17.05 | 18.76 | -8.71% | 13,379,400 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Piper Sandler Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $100 (opens in a new tab) Benzinga · 11 Nov 2026 06:04
- Favorable Medicare Coverage Ruling Drives CareDx’s (CDNA) Q3 Performance (opens in a new tab) Insider Monkey · 10 Nov 2026 18:18
- Should Earnings Upgrade Require Action From CareDx Stock Investors? (opens in a new tab) Simply Wall St. · 08 Nov 2026 07:12
- CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals (opens in a new tab) ChartMill · 07 Nov 2026 12:41
- CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab) 06 Nov 2026 21:05
- CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know (opens in a new tab) Zacks · 06 Nov 2026 16:00
- CareDx, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 03 Nov 2026 18:10
- CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth (opens in a new tab) Zacks · 03 Nov 2026 17:51
- CareDx (NASDAQ:CDNA): A Case for Affordable Growth (opens in a new tab) ChartMill · 03 Nov 2026 12:30
- CareDx Announces Third KOAR Analysis Published in Transplantation (opens in a new tab) 03 Nov 2026 12:05
- CareDx (CDNA) Stock Still Looks Reasonable Following Its Huge 3 Year Run (opens in a new tab) Simply Wall St. · 31 Oct 2026 14:15
- Why CareDx Stock Soared Today (opens in a new tab) Motley Fool · 30 Oct 2026 22:24
- CareDx (CDNA) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 30 Oct 2026 14:29
- CareDx, Inc Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 30 Oct 2026 12:30
- What CareDx (CDNA) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 30 Oct 2026 00:14
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 79.81 USD
- Market cap
- 4.2B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 9.5 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 33.68× | Weak | 30.56× |
| P/E (forward) | 51.02× | Weak | 14.16× |
| Price / book | 8.96× | Weak | 3.5× |
| Price / sales | 8.43× | Weak | 3.33× |
| EV / EBITDA | 154.93× | Weak | 11.19× |
| Free cash flow yield | 3.1% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 71% | Good | 54.9% |
| Operating margin | 1.6% | Weak | 5.8% |
| Net margin | 25.9% | Good | 1.2% |
| Return on equity | 33% | Good | 4.4% |
| Return on assets | 0.9% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 5.7% | Fair | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.06× | Good | 0.4× |
| Net debt / EBITDA | -8.64× | Good | 1.46× |
| Current ratio | 2.31× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow CDNA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.